Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Clinical trial NCT07008963 · COMPLETED

Trial details

NCT number: NCT07008963
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Metastatic Breast Cancer

Start date: 2025-07-31
Primary completion: 2025-11-28
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.